saquinavir mesylate

Known as: Monomethanesulfonate, Saquinavir, Saquinavir Monomethanesulfonate, Saquinavir Monomethanesulfonate [Chemical/Ingredient] 
A drug that belongs to the family of drugs called protease inhibitors. It interferes with the ability of a virus to make copies of itself.
National Institutes of Health

Related topics

Related topics

15 relations
Acquired Immunodeficiency SyndromeAstemizoleDrug AllergyErgotamines
Expand

Narrower (1)

Invirase

Broader (3)

IsoquinolinesQuinolinesSaquinavir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting.
The central nervous system (CNS) is an immunological privileged sanctuary site-providing reservoir for HIV-1 virus. Current anti… Expand
Is this relevant?
2014
2014
Intranasal in situ gel loaded with saquinavir mesylate nanosized microemulsion: preparation, characterization, and in vivo evaluation.
Saquinavir mesylate (SM) is a protease inhibitor with activity against human immunodeficiency virus type 1 (HIV-1) and is… Expand
Is this relevant?
2012
2012
Preparation and solid-state characterization of ball milled saquinavir mesylate for solubility enhancement.
Saquinavir is an anti-retroviral drug with very low oral bioavailability (e.g. 0.7-4.0%) due to its affinity toward efflux… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
Pharmacokinetics of saquinavir after intravenous and oral dosing of saquinavir: hydroxybutenyl-beta-cyclodextrin formulations.
The current research evaluated the ability of hydroxybutenyl-beta-cyclodextrin (HBenBCD) to enhance saquinavir in vitro… Expand
Is this relevant?
2006
2006
Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state.
A phase I study was conducted to formally evaluate the steady-state pharmacokinetics (PK) of tenofovir disoproxil fumarate (TDF… Expand
  • figure 1
  • figure 2
Is this relevant?
2004
2004
Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells.
Saquinavir mesylate (SQV) is the first-in-class and prototypical HIV protease inhibitor (PI) used in the treatment of HIV… Expand
Is this relevant?
2002
2002
Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2).
To determine if saquinavir mesylate (saquinavir) is a substrate of human multidrug resistance-associated protein 1 (hMRP1 [ABCC1… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.
BACKGROUND Predictors of virological response to highly active antiretroviral therapy (HAART) have never been systematically… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
1998
1998
Active Apical Secretory Efflux of the HIV Protease Inhibitors Saquinavir and Ritonavir in Caco-2 Cell Monolayers
AbstractPurpose. To investigate in vitro the mechanisms involved in the gastrointestinal absorption of the HIV protease inhibitor… Expand
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein.
Saquinavir, a peptidomimetic HIV protease inhibitor, has been shown to be effective in reducing patient viral load and reducing… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?